Jump to main content
Jump to site search

Issue 36, 2018
Previous Article Next Article

Self-assembly of folic acid dextran conjugates for cancer chemotherapy

Author affiliations


Folic acid (FA) has long been used as a specific targeting agent since many cancer cells overexpress folate receptors (FRs). Herein, novel functionalities of FA will be explored: directed self-assembly of nanoparticles for drug delivery together with pH responsive release. By conjugating with dextran (DEX), DEX-FA exerts a pH dependent self-assembly behavior: it self-associates into nanoparticles (NPs) around physiological pH (pH 7) and disassembles at higher pH (pH > 9). Doxorubicin (DOX), a model antitumor drug, has been successfully encapsulated via electrostatic interactions between DOX and FA. Moreover, the pH responsive release behaviors of DOX are controlled by FA. The DOX@DEX-FA NPs exhibit typical FA-FRs-mediated endocytosis in vitro and targeted delivery in vivo, altogether contributing to an enhanced antitumor efficacy, alleviated side effects, and elongated overall survival in a 4T1 subcutaneous tumor-bearing mouse model. The DOX@DEX-FA NPs have been demonstrated to be a simple, safe and efficient nanoplatform, holding significant translation potential for treating FR-overexpressing cancers. This study may present novel functionalities of FA in cancer-targeted nanotherapeutics.

Graphical abstract: Self-assembly of folic acid dextran conjugates for cancer chemotherapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 08 Jun 2018, accepted on 19 Aug 2018 and first published on 24 Aug 2018

Article type: Paper
DOI: 10.1039/C8NR04657C
Nanoscale, 2018,10, 17265-17274

  •   Request permissions

    Self-assembly of folic acid dextran conjugates for cancer chemotherapy

    Y. Tang, Y. Li, R. Xu, S. Li, H. Hu, C. Xiao, H. Wu, L. Zhu, J. Ming, Z. Chu, H. Xu, X. Yang and Z. Li, Nanoscale, 2018, 10, 17265
    DOI: 10.1039/C8NR04657C

Search articles by author